Dr. Ryan M. Klein, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Southern California Keck School of Medicine (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 510
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: University of Southern California Keck School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
CA license A0661244
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hoag Memorial Hospital Presbyterian Newport Beach, CA
Medical groups
- Huntington Beach Internal Medicine Group Inc (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 510
- Services billed
- 158,263
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, tezepelumab-ekko, 1 mg | 24,360 | 15 |
| Injection, mepolizumab, 1 mg | 23,500 | 23 |
| Injection, inclisiran, 1 mg | 10,508 | 22 |
| Injection, denosumab, 1 mg | 3,300 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,162 | 328 |
| Injection of drug or substance under skin or into muscle | 527 | 108 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 307 | 263 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 262 | 34 |
| Established patient office or other outpatient visit, 40-54 minutes | 225 | 223 |
| Test to measure expiratory airflow and volume | 212 | 163 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Rosuvastatin Calcium Other prescribers in Newport Beach, CA | 508 |
| Amlodipine Besylate Other prescribers in Newport Beach, CA | 443 |
| Atorvastatin Calcium Other prescribers in Newport Beach, CA | 291 |
| Levothyroxine Sodium Other prescribers in Newport Beach, CA | 287 |
| Metoprolol Succinate Other prescribers in Newport Beach, CA | 265 |
| Furosemide Other prescribers in Newport Beach, CA | 236 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Newport Beach, CA | 224 |
| Eliquis (apixaban) Other prescribers in Newport Beach, CA | 190 |
| Allopurinol Other prescribers in Newport Beach, CA | 184 |
| Prednisone Other prescribers in Newport Beach, CA | 164 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 153 payments worth $3,554 in total to this clinician.
| Genzyme Corporation | $739 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $466 |
| GlaxoSmithKline, LLC. | $346 |
| Amgen Inc. | $219 |
| Insmed, Inc. | $214 |
| Ani Pharmaceuticals, Inc. | $202 |
| AbbVie Inc. | $192 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $184 |
| Food and Beverage | $3,416 |
|---|---|
| Travel and Lodging | $138 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Feb 28, 2025 | Travel and Lodging travel to Chicago, IL Company’s descriptionResearch Related Service | $53.19 |
| AstraZeneca Pharmaceuticals LP Feb 28, 2025 | Travel and Lodging travel to Chicago, IL Company’s descriptionResearch Related Service | $51.32 |
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Travel and Lodging travel to Chicago, IL Company’s descriptionResearch Related Service | $33.91 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 45 industry-funded studies in 2025, from 15 companies. The companies reported $1,561,623 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulm…
AstraZeneca Pharmaceuticals LP - A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis (AirleafTM)
Boehringer Ingelheim Pharmaceuticals, Inc. - Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Insmed, Inc. · Completed · NCT04677569 - A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. in patients with bronchiectasis (ClairleafTM)
Boehringer Ingelheim Pharmaceuticals, Inc. - Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics Corporation · Recruiting · NCT05943535 - A prospective, real-world, interventional study to evaluate the effect
GlaxoSmithKline, LLC. - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary D…
AstraZeneca Pharmaceuticals LP - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - A phase 2, randomized, double-blind, placebo-controlled, parallel grou
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.